Pharvaris N.V. ( (PHVS) ) has released its Q4 earnings. Here is a breakdown of the information Pharvaris N.V. presented to its investors.
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to treat bradykinin-mediated diseases such as hereditary angioedema (HAE). The company recently reported its financial results for the fourth quarter and full year of 2024, alongside significant business updates.
Pharvaris achieved target enrollment in its pivotal Phase 3 RAPIDe-3 study for the on-demand treatment of HAE attacks and is progressing with the CHAPTER-3 study for prophylaxis of HAE attacks, with topline data expected in the second half of 2026. The European Commission granted orphan medicinal product designation to their lead candidate, deucrictibant, reinforcing its potential in treating bradykinin-mediated angioedema.
Financially, Pharvaris maintains a strong position with €281 million in cash and cash equivalents as of December 31, 2024. However, the company reported increased research and development expenses, totaling €98.6 million for the year, and a net loss of €134.2 million, reflecting its ongoing investment in clinical development.
Looking ahead, Pharvaris remains committed to advancing its clinical programs and addressing unmet medical needs in bradykinin-mediated angioedema. The company’s management is optimistic about the potential impact of deucrictibant and continues to focus on generating robust clinical data to support its development.